• Hung-Chen Wang, Yu-Tsai Lin, Wei-Che Lin, Ren-Wen Ho, Yu-Jun Lin, Nai-Wen Tsai, Jih-Tsun Ho, and Cheng-Hsien Lu.
• Department of Neurosurgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
• World Neurosurg. 2018 Jun 1; 114: e766-e774.

BackgroundA standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG). Several studies demonstrated that prolonged TMZ treatment increased survival for these patients.MethodsThis retrospective study aimed to compare changes in tumor volume during and after adjuvant TMZ treatment and overall survival (OS).ResultsThere were 90 patients were administered adjuvant TMZ treatment. Comparing average tumor volume changes during TMZ treatment and after TMZ was stopped, a significant decrease in tumor volume was observed during TMZ treatment in the total patient population, the anaplastic astrocytoma (AA) group, and the glioblastoma multiforme (GBM) group (P ≤ 0.001, P = 0.042, and P = 0.005, respectively). Median overall survival was 78.4 weeks, which was significant regarding the surgical tumor resection rate (r = 0.241; P = 0.04) and total TMZ treatment cycles (r = 0.631; P ≤ 0.001).ConclusionsDuring adjuvant TMZ treatment, tumor volume decreased significantly (P = 0.042, and P = 0.005, respectively) in patients with GBM and AA. Prolonged TMZ administration improved OS, without increased toxicity.Copyright © 2018 Elsevier Inc. All rights reserved.

30 keywords...

hide…